Keywords :
Akathesia, Amisulpride, Case report, Deliberate self-harm, Tardive dyskinesia
Citation Information :
Goswami D, Ghosh S, Nayak D. A Case Report on Multiple Episodes of Deliberate Self-harm in a Patient with Amisulpride-associated Akathisia and Tardive Dyskinesia. Ind J Priv Psychiatry 2024; 18 (2):98-100.
Tardive dyskinesia is a movement disorder that causes involuntary, repetitive body movements and is commonly seen in patients who are on long-term treatment with antipsychotic medications. It occurs in 20–50% of patients taking APDs. Akathisia is a neuropsychiatric syndrome characterized by subjective and objective psychomotor restlessness whose severity can extend to self-harm and suicide.
Case description: Our index case, a 57 years old, Hindu married female, of lower socio-economic status, diagnosed as a case of schizophrenia for 2 years, and well maintained on Tab. Amisulpride 600 mg daily, came in July 2022, with complaints of pain and upper abdominal discomfort and distension of abdomen for which she was prescribed Levosulpiride 50 mg daily. On next visit, in October 2022, she was having dyskinetic movements of the lips and rhythmic protrusion of the tongue, along with rhythmic movement of the whole abdomen. Eventually, she was diagnosed as a case of Levosulpiride-induced Tardive Dyskinesia and Levosulpiride was stopped. Tetrabenazine 50 mg daily was started. Subsequently, she became very restless and complained of uneasiness of whole body. Due to severe uneasiness and restlessness, she attempted suicide three times in presence of her family members and thus was prevented. In March 2023, she was having dyskinetic movement of oral cavity and rhythmic involuntary movement of the abdomen and was restless and irritable. She was continuing Amisulpride 600 mg and Tetrabenazine 50 mg daily. But unfortunately, there was no symptomatic improvement. NARANJO assessment score was applied which showed probable drug reaction. Then, it was diagnosed as a case of Amisulpride-induced Tardive Dyskinesia with Akathisia. Amisulpride was also stopped and no antipsychotics were given. For Akathisia, Lorazepam 4 mg in divided doses and Propranolol 40 mg was added to Tetrabenazine 75 mg daily. Now, patient started improving, having no fresh complaints although presently not on antipsychotics.
Daniel DG, Egan MF, Wolf SS. Neuropsychiatric aspects of movement disorders. In: Comprehensive Textbook of Psychiatry. Edition 7, Lippincott Williams and Wilkins, Philadelphia, USA. 2000.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Edition 4, Text Revision (DSM-IV-TR). Washington, DC. 2000:803–805.
Raja M, Azzoni A, Lubich L. Aggressive and violent behavior in a population of psychiatric inpatients. Soc Psychiatry Psyhiatr Epidemiol 1997;32(7):428–434. DOI: 10.1007/BF00788184.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–245. DOI: 10.1038/clpt.1981.154.
Chow CL, Kadouh NK, Bostwick JR, et al. Akathisia and newer second-generation antipsychotic drugs: A review of current evidence. Pharmacotherapy 2020;40(6):565–574. DOI: 10.1002/phar.2404.
Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment. J Psychopharmacol 1998;12(2):192–214. DOI: 10.1177/026988119801200212.
Ferré S, Guitart X, Quiroz C, et al. Akathisia and restless legs syndrome: Solving the dopaminergic paradox. Sleep Med Clin 2021;16(2): 249–267. DOI: 10.1016/j.jsmc.2021.02.012.
Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000;61(14):5–10. PMID: 11154018.
Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arc Gen Psychiatry 20031;60(6):553–564. DOI: 10.1001/archpsyc.60.6.553.
McKeage K, Plosker GL. Amisulpride: A review of its use in the management of schizophrenia. CNS Drugs 2004;18(13):933–956. DOI: 10.2165/00023210-200418130-00007.
Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158(3):360–369. DOI: 10.1176/appi.ajp.158.3.360.
Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual “atypical” antipsychotic: A meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159(2):180–190. DOI: 10.1176/appi.ajp.159.2.180.
Ghosh S, Nayek S. A case of levosulpiride-induced tardive dyskinesia. Open Journal of Psychiatry & Allied Sciences 2019;10(2):169–171. DOI: 10.5958/2394-2061.2019.00024.7.
Choudhury S, Chatterjee K, Singh R, et al. Levosulpiride-induced movement disorders. Journal of Pharmacology and Pharmacotherapeutics 2017;8(4):177–181. DOI: 10.4103/jpp.JPP_32_17.
Mathews M, Gratz S, Adetunji B, et al. Antipsychotic-induced movement disorders: Evaluation and treatment. Psychiatry (Edgmont) 2005;2(3):36–41. PMID: 21179628.